MET Amplification in Non-Small Cell Lung Cancer (NSCLC)—A Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting.

Autor:	Schubart, Christoph, Stöhr, Robert, Tögel, Lars, Fuchs, Florian, Sirbu, Horia, Seitz, Gerhard, Seggewiss-Bernhardt, Ruth, Leistner, Rumo, Sterlacci, William, Vieth, Michael, Seidl, Christoph, Mugler, Michael, Kapp, Markus, Hohenforst-Schmidt, Wolfgang, Hartmann, Arndt, Haller, Florian, Erber, Ramona
Předmět:	LUNG cancer & genetics LUNG cancer diagnosis NATURAL immunity SEQUENCE analysis GENETIC mutation CELL receptors INDIVIDUALIZED medicine EPITHELIAL-mesenchymal transition FLUORESCENCE in situ hybridization POLYMERASE chain reaction GENE amplification DRUG resistance in cancer cells
Zdroj:	Cancers; Oct2021, Vol. 13 Issue 19, p5023, 1p
Abstrakt:	Simple Summary: Lung cancer has a high incidence and affects both men and women. Targeted therapy options directed at certain mutant proteins, and which avoid systemic chemotherapy are already available and emerging. The gene mesenchymal epithelial transition (MET), encoding a receptor tyrosine kinase protein, is amplified in a subpopulation of lung cancer patients. The aim of our consecutive study was to assess whether next-generation sequencing (NGS) is a reliable method for the detection of MET gene copy number. Our study confirmed that NGS is able to detect cases harboring a high-level MET gene amplification but is unreliable and fails to detect the various levels of MET gene amplification. Therefore, NGS cannot replace the gold standard method of fluorescence in situ hybridization for the detection of MET gene copy number. In non-small cell lung cancer (NSCLC), approximately 1–3% of cases harbor an increased gene copy number (GCN) of the MET gene. This alteration can be due to de novo amplification of the MET gene or can represent a secondary resistance mechanism in response to targeted therapies. To date, the gold standard method to evaluate the GCN of MET is fluorescence in situ hybridization (FISH). However, next-generation sequencing (NGS) is becoming more relevant to optimize therapy by revealing the mutational profile of each NSCLC. Using evaluable n = 205 NSCLC cases of a consecutive cohort, this study addressed the question of whether an amplicon based NGS assay can completely replace the FISH method regarding the classification of MET GCN status. Out of the 205 evaluable cases, only n = 9 cases (43.7%) of n = 16 high-level MET amplified cases assessed by FISH were classified as amplified by NGS. Cases harboring a MET GCN > 10 showed the best concordance when comparing FISH versus NGS (80%). This study confirms that an amplicon-based NGS assessment of the MET GCN detects high-level MET amplified cases harboring a MET GCN > 10 but fails to detect the various facets of MET gene amplification in the context of a therapy-induced resistance mechanism. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.